Moreover, the therapeutic promise of targeting the NLRP3 inflammasome also extends to oncology; studies show that, depending on the tumour environment, altering this pathway can either promote or hinder the proliferation of cancer cells (Missiroli et al. 2021). The gene discussed is NLRP3; the disease is neoplasm.